Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma.

Area of Science:

• Pediatric Oncology
• Mathematical Biology
• Computational Pharmacology

Background:

• Neuroblastoma is a common childhood extra-cranial solid tumor with poor outcomes for high-risk patients.
• Current multi-modal therapy, including standard induction chemotherapy (rapid COJEC), shows heterogeneous results due to tumor resistance.
• A one-size-fits-all approach fails to account for individual tumor characteristics and drug resistance mechanisms.

Purpose of the Study:

• To develop a mathematical model simulating neuroblastoma clonal evolution under chemotherapy.
• To devise an optimization algorithm for personalized chemotherapy scheduling.
• To explore strategies for enhancing multi-modal therapy for neuroblastoma.

Main Methods:

• Formulated a mathematical model using ordinary differential equations to describe tumor clonal evolution and drug pharmacokinetics.
• Incorporated genetic and phenotypic drug resistance into the model.
• Developed an optimization algorithm to determine optimal chemotherapy schedules based on pre-treatment tumor composition.

Main Results:

• Optimized schedules exploit drug cytotoxicity differences and intra-tumoral clonal competition.
• Personalized schedules demonstrated potential for maximal tumor shrinkage during induction chemotherapy.
• The study highlights the benefit of individualized treatment over standard regimens.

Conclusions:

• Personalized chemotherapy schedules can significantly improve induction chemotherapy outcomes for neuroblastoma.
• Integrating targeted therapies against chemotherapy-induced mutations may enhance overall treatment efficacy.
• A decision support system using patient-specific modeling and emerging technologies is crucial for clinical translation.